Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

DISEASE CHARACTERISTICS: Histologically confirmed renal cell carcinoma (RCC) Clear cell or papillary RCC Granular tumors with sarcomatoid features No purely sarcomatoid RCC, chromophobic RCC, or oncocytoma No transitional cell carcinoma of the renal pelvis and collecting systems Metastatic or unresectable disease At least 1 measurable lesion At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan The following are not considered measurable: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions Primary bladder masses Progressive disease after interferon alfa and/or interleukin-2 for metastatic RCC OR intolerance to these therapies No prior or concurrent CNS metastases Negative MRI of the brain within the past 28 days Must have HLA-identical (6/6) sibling donor PATIENT CHARACTERISTICS: Age: 60 and under Performance status: ECOG 0-1 Life expectancy: More than 6 months Hematopoietic: Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST no greater than 3 times ULN Renal: Creatinine clearance at least 40 mL/min Cardiovascular: LVEF at least 45% by MUGA or echocardiogram Pulmonary: DLCO greater than 40% of predicted (corrected for hemoglobin level) No symptomatic pulmonary disease Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No known hypersensitivity to E. coli-derived products No uncontrolled diabetes mellitus No active serious infection No other concurrent malignancy except non-melanoma skin cancer or other malignancy that has less than a 30% risk of relapse after completion of therapy PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No concurrent sargramostim (GM-CSF) Concurrent epoetin alfa allowed Chemotherapy: No other concurrent chemotherapy Endocrine therapy: At least 28 days since prior hormonal therapy (e.g., megestrol, corticosteroids, or anti-estrogen therapy) Concurrent steroids allowed for adrenal failure, graft-versus-host disease, or other nondisease-related conditions (e.g., insulin for diabetes) Radiotherapy: At least 14 days since prior radiotherapy Surgery: At least 14 days since prior surgery Other: At least 28 days since prior systemic therapy for RCC Recovered from prior therapy